Inhibition of EGFR signaling in prostate cancer treated with EGFR siRNA and Gefitinib

Life Science Journal

Volumn 9, Issue 2, 2012, Pages 544-552

  Chen, Weiguo ^a   Xie, Donghua ^b   Hou, Jianquan ^a   Long, Huiming ^a   Li, Gang ^a   Pu, Jinxian ^a   Ouyang, Jun ^a   Wu, Yi ^a  

^a SOOCHOW UNIVERSITY   (China)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Epidermial growth factor receptor; Gefitinib; Prostate cancer; Small interfering RNA; Therapy

Indexed keywords

EID: 84874837694     PISSN: 10978135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Shteynshlyuger A, Andriole GL. Prostate cancer: to screen or not to screen? Urol Clin North Am. 2010; 37: 1-9.
2. Traish AM, Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 2009; 101:1949-56
3. Kim JH, Xu C, Keum YS, Reddy B, Conney A, Kong AN. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with b-phenylethyl isothiocyanate and curcumin. Carcinogenesis, 2006, 27:475-482.
4. Hynes NE, Mac Donald G. Erb B receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009; 21:177-84.
5. Iain RH, Janice MK, Helen EJ, et al. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer, 2006, 13:S89-S97.
6. Naldini L. In vivo gene delivery by lentiviral vectors. Thromb Haemost 1999; 82:552-554.
7. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clinical Cancer Research. 2004, 10:1212-1218.
8. Angelucci A, Gravina GL, Rucci N, Millimaggi D, Festuccia C, Muzi P, Teti A, Vicentini C, Bologna M. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocrine-related Cancer, 2006, 13:197-210.
9. Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res. 2007; 13:6579-84.
10. Festuccia C, Gravina GL, Biordi L, et al. Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Prostate. 2009; 69:1529-37.
11. Addepalli MK, Ray KB, Kumar B, et al. RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. Gene Ther. 2010; 17:352-9.
12. de Muga S, Hernández S, Agell L, et al. Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas. Mod Pathol. 2010; 23:703-12.
13. Naldini L. In vivo gene delivery by lentiviral vectors. Thromb Haemost 1999; 82:552-4.
14. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, Sergi Sergi L, Benedicenti F, Ambrosi A, Di Serio C, Doglioni C, von Kalle C, Naldini L. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24:687-96.
15. McClellan M, Kievit P, Auersperg N, Rodland K. Regulation of proliferation and apoptosis by epidermal growth factor and protein kinase C in human ovarian surface epithelial cells. Exp Cell Res 1999; 246:471-9.
16. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, Ono M. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62:2554-60.
17. Bates SE, Fojo T. Epidermal growth factor receptor inhibitors: a moving target? Clin Cancer Res 2005; 11:7203-5.
18. Yarden Y, Sliwkowski M. Untangling the Erb B signaling network. Nat Rev Mol Cell Biol 2001; 2:127-37.
19. Liebmann C. Regulation of MAP kinase activity by peptide receptor signaling pathway: paradigms of multiplicity. Cell Signal 2001; 13:777-85. Gaestel M. MAPKAP kinases IMKs Itwo's company, three's a crowd. Nat Rev Mol Cell Biol 2006; 7:120-30.
20. Wu Z, Gioeli D, Conaway M, et al. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate. 2008; 68:935-44.
21. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced nonsmall-cell lung cancer. J Natl Cancer Inst, 2004, 96: 1133-1141.
22. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, Kuwano M. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell linesco rrelates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004; 3: 465-72.
23. Uramoto H and Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer. 2007, 96, 857-863.
24. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133-44.
25. Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 2005; 65:3003-10.